Clinical data | |||
---|---|---|---|
Trade names | Platinol, others | ||
Other names | Cisplatinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum(II) (CDDP) | ||
AHFS/Drugs.com | Monograph | ||
MedlinePlus | a684036 | ||
License data | |||
Pregnancy category | |||
Routes of administration | Intravenous | ||
ATC code | |||
Legal status | |||
Legal status | |||
Pharmacokinetic data | |||
Bioavailability | 100% (IV) | ||
Protein binding | > 95% | ||
Elimination half-life | 30–100 hours | ||
Excretion | Renal | ||
Identifiers | |||
| |||
CAS Number | |||
PubChem CID | |||
DrugBank | |||
ChemSpider | |||
UNII | |||
KEGG | |||
ChEBI | |||
ChEMBL | |||
PDB ligand | |||
CompTox Dashboard (EPA) | |||
ECHA InfoCard | 100.036.106 | ||
Chemical and physical data | |||
Formula | [Pt(NH3)2Cl2] | ||
Molar mass | 300.05 g·mol−1 | ||
3D model (JSmol) | |||
| |||
| |||
(what is this?) (verify) |
Cisplatin is a chemical compound with formula cis-[Pt(NH3)2Cl2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers.[3] These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma.[3] It is given by injection into a vein.[3]
Common side effects include bone marrow suppression, hearing problems including severe hearing loss, kidney damage, and vomiting.[3][4][5] Other serious side effects include numbness, trouble walking, allergic reactions, electrolyte problems, and heart disease.[3] Use during pregnancy can cause harm to the developing fetus.[1][3] Cisplatin is in the platinum-based antineoplastic family of medications.[3] It works in part by binding to DNA and inhibiting its replication.[3]
Cisplatin was first reported in 1845 and licensed for medical use in 1978 and 1979.[6][3] It is on the World Health Organization's List of Essential Medicines.[7][8]